The Artificial Intelligence In Digital Genome Market is estimated to be valued at US$ 269.8 million in 2023 and is expected to exhibit a CAGR of 44.8% over the forecast period of 2023-2028, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Artificial intelligence facilitates the analysis of genomic data and helps discover meaningful patterns for disease diagnosis and drug development. AI in genomics is used for various applications such as genome analysis, precision medicine, non-invasive prenatal testing, and drug discovery. It aids in the detection of genetic variants, identification of disease-causing genes, and helps predict disease risks and drug responses at an individual level with high accuracy.

Market Dynamics:
Growing demand for personalized medicine: Advances in genomics and artificial intelligence have enabled the discovery of genetic basis of diseases and development of personalized treatment plans. AI aids in analyzing massive amounts of genomic and clinical data to provide tailored treatment and care based on an individual's genetic profile. This is expected to drive the demand for AI in digital genome solutions over the forecast period.
Advancements in AI and genomics technologies: Continuous technological advancements are improving computational capabilities for analyzing large genomic datasets. Developments in areas such as machine learning, deep learning, and cloud computing are making AI more efficient and scalable for precision medicine applications. Moreover, next-generation sequencing technologies are making whole genome sequencing affordable and widely accessible. These technological developments are supporting the integration of AI and genomics.

Read More - https://makuv.com/artificial-intelligence-in-healthcare-contributing-large-share/